Clinic-based ART Diagnostic Evaluation (CLADE)
|ClinicalTrials.gov Identifier: NCT01791556|
Recruitment Status : Unknown
Verified February 2013 by Walter Reed Army Institute of Research (WRAIR).
Recruitment status was: Active, not recruiting
First Posted : February 15, 2013
Last Update Posted : February 15, 2013
|Condition or disease||Intervention/treatment||Phase|
|Acquired Immunodeficiency Syndrome HIV Infection RNA Virus Infections Virus Diseases||Other: HIV-1 viral load testing||Not Applicable|
The Kenya Ministry of Health (MoH) guidelines for antiretroviral therapy (ART) and manual for ART providers recommend targeted viral load monitoring in ART management. While only limited use of viral load monitoring exist due to limitations in technical and financial resources, the feasibility and cost-effectiveness of viral load monitoring has not been prospectively studied in ART roll-out at the clinic level.
"Clinic-based ART Diagnostic Evaluation" (CLADE) is an unblinded, randomized (1:1), prospective, observational, cohort public health evaluation (PHE) aimed at evaluating the superiority and cost-effectiveness of two recommended Ministry of Health ART diagnostic evaluation approaches at the clinic level in adult treatment naive patients beginning Ministry of Health approved first-line ART: "routine care", the most common approach to ART roll-out where clinical (World Health Organization) staging and immunological (CD4) monitoring are the primary baseline and follow-up evaluations and targeted viral load monitoring; and "viral load care", where routine viral loads are included with clinical and immunological evaluations.
In this study we plan to enroll 820 adult participants starting ART, 410 people will be enrolled in each of the public health evaluation arms. Arm A/ "routine care" will receive MoH standard of care monitoring consisting of baseline CD4 and WHO staging every 6 months, or as clinically indicated, with CD4 and WHO staging criteria guiding care and treatment in addition to routine clinical evaluations. In addition, MoH criteria for targeted viral load monitoring will be used. Arm B/ "viral load guided care" will receive MoH standard of care as in Arm A but also have routine viral load monitoring at baseline and every 6 months, or as clinically indicated, to guide care and treatment. Each arm will receive Kenya Ministry of Health first-line ART. Participants meeting MoH criteria for treatment failure will being second-line ART.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||820 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Clinic-based ART Diagnostic Evaluation|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||August 2012|
|Estimated Study Completion Date :||August 2014|
No Intervention: Standard of Care
clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months with confirmatory or targeted viral load monitoring based upon Kenya Ministry of Health and World Health Organization guidelines
Experimental: HIV-1 viral load testing
viral load in addition to clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months
|Other: HIV-1 viral load testing|
- Viral failure [ Time Frame: 18 months on follow-up ]
- The study primary endpoint is viral failure at the 18 month follow-up visit as defined by VL>1000 copies/mL by the viral load platform approved by the Kenya Medical Research Institute/ Walter Reed Project Clinical Research Center laboratory under the College of American Pathologist and related external quality assurance programs.
- Relative cost-effectiveness of routine viral load monitoring in addition to CD4 count and clinical monitoring compared to CD4 and clinical alone in clinic-based ART management
- Viral failures [ Time Frame: 18 months on follow-up ]
- Combined clinical outcome as defined by 2 new World Health Organization stage III events or 1 new World Health Organization stage IV event.
- Death (as confirmed by medical records or death certificate).
- Hospitalization (for any illness).
- Opportunistic infections (onset after study entry).
- Adherence (routinely captured by clinics).
- Lost of follow-up (defined as missing 2 consecutive appointments and/or inability to have final study visit).
- HIV genotype resistance in all treatment failures and all viral failures at the final study visit.
- Feasibility of rolling out viral load monitoring in rural district-level ART clinics (based upon knowledge, attitudes, and performance indicators.)
- Cost of viral load monitoring (in addition to CD4 count and clinical care monitoring as actual costs collected during 18 months of follow-up on ART).
- Adherence to GCP (as a research study is incorporated in to ART clinics and based upon GCP indicators).
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01791556
|Kenya Medical Research Institute/ Walter Reed Project HIV Program|
|Principal Investigator:||Fredrick Sawe, MBChB, MMED||Kenya Medical Research Institute/ Walter Reed Project|
|Principal Investigator:||Douglas Shaffer, MD,MHS||Kenya Medical Research Institute/ Walter Reed Project|